COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge

B cell-targeting strategies such as rituximab are widely used in B cell hematologic malignancies, rheumatologic and musculoskeletal diseases and a variety of autoimmune disorders. The purpose of this paper is to illustrate how exposure to anti-CD20 treatment profoundly affects B cell functions invol...

Descripción completa

Detalles Bibliográficos
Autores principales: Furlan, Anna, Forner, Gabriella, Cipriani, Ludovica, Vian, Elisa, Rigoli, Roberto, Gherlinzoni, Filippo, Scotton, Piergiorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595333/
https://www.ncbi.nlm.nih.gov/pubmed/34804051
http://dx.doi.org/10.3389/fimmu.2021.763412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595333/
https://www.ncbi.nlm.nih.gov/pubmed/34804051
http://dx.doi.org/10.3389/fimmu.2021.763412

Ejemplares similares